PMID- 21996342
OWN - NLM
STAT- MEDLINE
DCOM- 20120703
LR  - 20220330
IS  - 1097-6825 (Electronic)
IS  - 0091-6749 (Linking)
VI  - 129
IP  - 1
DP  - 2012 Jan
TI  - Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced 
      rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study.
PG  - 128-35
LID - 10.1016/j.jaci.2011.08.036 [doi]
AB  - BACKGROUND: Epicutaneous allergen administration using a patch may be an 
      alternative to subcutaneous or sublingual immunotherapy. OBJECTIVE: To optimize 
      treatment dose and to demonstrate the efficacy and safety of epicutaneous 
      immunotherapy. METHODS: This monocentric, placebo-controlled, double-blind trial 
      included 132 patients with grass pollen-induced rhinoconjunctivitis. In February 
      2008, patients were randomly allocated to receive placebo or 3 different doses of 
      allergen. Before and during the pollen season 2008, patients received 6 weekly 
      patches. Efficacy was assessed 4 to 5 months later (n = 110) and during the 
      pollen season of the treatment-free follow-up year in 2009 (n = 93). The primary 
      outcome was patient-reported changes in hay fever symptoms assessed by a visual 
      analog scale. Secondary outcome measures were weekly visual analog scale symptom 
      scores during pollen season, use of rescue medication, changes in conjunctival 
      and skin reactivity, as well as safety. RESULTS: Hay fever symptoms during the 
      pollen season were reduced by more than 30% in 2008 and by 24% in 2009 in the 
      high-dose group as compared with that in the placebo group, and the alleviation 
      of symptoms in the follow-up year was dependent on the treatment dose. Higher 
      allergen doses were associated with drug-related adverse events (AEs), 
      predominantly manifested by pruritus, erythema, wheal, or eczema. Eleven systemic 
      AEs of grades 1 to 2 required treatment and led to study exclusion. The dropout 
      rate due to AEs was 8.3%. No drug-related serious AE was recorded. CONCLUSION: 
      Epicutaneous immunotherapy is safe and efficacious in a dose-dependent manner 
      after 6 patches only.
CI  - Copyright (c) 2011 American Academy of Allergy, Asthma & Immunology. Published by 
      Mosby, Inc. All rights reserved.
FAU - Senti, Gabriela
AU  - Senti G
AD  - Clinical Trials Center, University Hospital Zurich, Zurich, Switzerland.
FAU - von Moos, Seraina
AU  - von Moos S
FAU - Tay, Fabian
AU  - Tay F
FAU - Graf, Nicole
AU  - Graf N
FAU - Sonderegger, Theodor
AU  - Sonderegger T
FAU - Johansen, Pal
AU  - Johansen P
FAU - Kundig, Thomas M
AU  - Kundig TM
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20111013
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Allergens)
SB  - IM
MH  - Administration, Cutaneous
MH  - Adult
MH  - Allergens/*immunology
MH  - Conjunctivitis, Allergic/immunology/*therapy
MH  - *Desensitization, Immunologic/adverse effects
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Poaceae/*immunology
MH  - Pollen/*immunology
MH  - Treatment Outcome
EDAT- 2011/10/15 06:00
MHDA- 2012/07/04 06:00
CRDT- 2011/10/15 06:00
PHST- 2011/03/31 00:00 [received]
PHST- 2011/08/18 00:00 [revised]
PHST- 2011/08/25 00:00 [accepted]
PHST- 2011/10/15 06:00 [entrez]
PHST- 2011/10/15 06:00 [pubmed]
PHST- 2012/07/04 06:00 [medline]
AID - S0091-6749(11)01404-7 [pii]
AID - 10.1016/j.jaci.2011.08.036 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2012 Jan;129(1):128-35. doi: 10.1016/j.jaci.2011.08.036. 
      Epub 2011 Oct 13.